Production of human basic fibroblast growth factor using Bacillus subtilis and endonucleases.
The use of a trans-splicing intein from Anabaena DNA polymerase III unit in Bacillus subtilis for bFGF expression addresses the cost and yield challenges, achieving high-purity and biologically active bFGF production through optimized expression and purification.
Patent Information
- Application Number
- JP2022523843
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-11
- Filing Date
- 2021-02-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-02-03
AI Technical Summary
The high production cost and low yield of human basic fibroblast growth factor (bFGF) protein hinder its commercial use in the pharmaceutical industry due to instability in stem cell culture conditions and the presence of endotoxins in Escherichia coli expression systems, while Bacillus subtilis, despite being endotoxin-free, faces challenges with protease expression and lower foreign protein yields.
A nucleic acid construct incorporating a trans-splicing intein from Anabaena DNA polymerase III unit (Asp DnaE) with a short peptide affinity tag is used in Bacillus subtilis to express bFGF, followed by cation exchange chromatography and heparin-agarose chromatography for purification.
This method enhances bFGF expression levels and purity, reducing production costs and ensuring biological activity, suitable for large-scale production with improved yield and reduced inclusion body formation.
Smart Images

Figure 0007586517000003 
Figure 0007586517000004 
Figure 0007586517000005
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biology, and generally to systems and methods for expressing foreign polypeptides. [Background technology]
[0002] Efficient and cost-effective expression of native foreign polypeptides, especially cytokines, is becoming more and more important in cell biology (e.g., stem cell research). Here, human basic fibroblast growth factor (abbreviated as bFGF, also called FGF2) is taken as an example. bFGF is a member of the fibroblast growth factor family and has many therapeutic applications in neurodegenerative diseases, heart diseases, and wound-based lesions that are difficult to heal. bFGF also plays an important role in tissue development by inducing the proliferation of fibroblasts and stem cells. Furthermore, bFGF also plays an important role in large-scale production of stem cells. However, at present, the high production cost and low production yield of bFGF protein hinder commercial use in the pharmaceutical industry. For example, bFGF protein is unstable in stem cell culture conditions and is easily degraded. In addition, regular replacement of the medium with fresh medium containing commercially available bFGF significantly increases development costs. Therefore, in order to promote the development of stem cell research, it is extremely important to improve the upstream production efficiency of recombinant human bFGF.
[0003] Escherichia coli (E. coli) is widely used as a bacterial host for the expression of recombinant proteins that are not post-translationally modified. E. coli has the advantages of fast growth rate, low cost, and ease of use, which makes it widely used in the biotechnology field. However, since E. coli is a Gram-negative bacterium with an LPS outer membrane, purified recombinant proteins generally contain large amounts of endotoxins. These endotoxins may have undesirable toxic effects when the relevant recombinant proteins are used in therapeutic tissue culture samples or animal subjects. Endotoxins are difficult to separate in downstream purification processes unless endotoxin-free water or endotoxin removal kits are used. Therefore, relevant reagent kits are used, which increases the production costs of the target protein.
[0004] On the other hand, Bacillus subtilis is a gram-positive bacterium that does not contain endotoxins and is therefore "generally recognized as safe" (GRAS) by the FDA. Bacillus subtilis is capable of stably expressing foreign polypeptides, and processes have already been developed for expressing secreted endogenous and foreign proteins. However, recombinant foreign proteins are expressed at lower levels in Bacillus subtilis than in E. coli. The main reasons for this are as follows:
[0005] 1. Bacillus subtilis expresses and secretes large amounts of proteases during the late logarithmic growth phase, which adversely affects the stable expression and production amount of foreign proteins.
[0006] 2. Some foreign proteins are secreted into the medium and affect the growth of the host bacteria, which in turn affects the efficient expression of the foreign proteins.
[0007] 3. Genetic engineering is difficult compared to E. coli.
[0008] These factors are believed to limit the use of Bacillus subtilis as a host cell.
[0009] Inteins are internal protein elements that are automatically excised from host proteins and catalyze the ligation of flanking sequences (exteins) through peptide bonds. Intein excision does not require post-translational processing of auxiliary enzymes or cofactors. This process of automatic excision is called "protein splicing". The inner part of the protein sequence is called the "intein" and the outer part of the protein sequence is called the "extein". The upstream extein is called the "N-extein" and the downstream extein is called the "C-extein".
[0010] Inteins in proteins are not only used to enhance the content of post-translational processing of genetic information, but are also widely used in protein purification. Inteins are divided into two types depending on whether or not they contain a homing endonuclease domain. One type is a maxi-intein, which has protein splicing activity and a homing endonuclease sequence. The other type is a mini-intein, which has only protein splicing activity. Inteins are also divided into integral inteins and split inteins depending on their form of existence. The former has two splicing regions present in the same polypeptide fragment. In contrast, the latter has two splicing regions present in different polypeptide fragments, and is therefore called a split intein or split intein. An integral intein performs cis-splicing, while a split / split intein performs trans-splicing.
[0011] Inteins are widely used in protein purification, and more than 400 types of inteins have been discovered in living organisms to date. In addition, multiple inteins with different sources and structures are used to create protein expression and purification systems. The cleavage reaction rate and conditions vary depending on the intein, and there are also large differences in purification efficiency. However, the factors that affect intein cleavage have not yet been fully elucidated. Summary of the Invention [Problem to be solved by the invention]
[0012] There is a need in the art for systems and methods that allow for cost-effective expression of foreign polypeptides. [Means for solving the problem]
[0013] In one embodiment, the present invention provides a nucleic acid construct, comprising an insert, the insert comprising, from its 5' end to its 3' end, a polynucleotide sequence encoding a short peptide affinity tag, a trans-splicing intein derived from Anabaena sp., and a foreign polypeptide, the short peptide affinity tag being the N-extein of the trans-splicing intein, and the foreign polypeptide being the C-extein of the trans-splicing intein.
[0014] In one aspect, the intein is an Anabaena DNA polymerase III unit intein (Asp DnaE).
[0015] In one aspect, the intein comprises or consists of an amino acid sequence having at least 75% sequence identity to SEQ ID NO:2.
[0016] In one aspect, the foreign polypeptide is a fibroblast growth factor (FGF), such as basic fibroblast growth factor (bFGF), particularly human bFGF.
[0017] In one aspect, the short peptide affinity tag has a length of about 4-15 amino acids, for example a 5-15xHis tag, in particular a 6xHis tag.
[0018] In one aspect, the nucleic acid construct further comprises one or more of the following elements: a promoter, an operon, an enhancer, and a ribosome binding site.
[0019] In one aspect, the nucleic acid construct comprises a nucleotide sequence encoding from the 5' to 3' end: T7 promoter-lactose operon-ribosome binding site (RBS)-6xHis tag-Asp DnaE intein-bFGF-T7 transcription terminator.
[0020] In one aspect, the nucleic acid construct further comprises a first cloning site located upstream of the insert and a second cloning site located downstream of the insert, the first and second cloning sites allowing for insertion of the nucleic acid construct into an expression vector.
[0021] In another embodiment, the present invention provides an expression vector comprising the nucleic acid construct of the present invention.
[0022] In another embodiment, the present invention provides a transformed Bacillus subtilis comprising an expression vector of the present invention.
[0023] In another embodiment, the present invention provides a method for producing a foreign polypeptide, the method comprising culturing a transformed Bacillus subtilis of the present invention under conditions allowing expression of the foreign polypeptide.
[0024] In one aspect, the above-mentioned method for producing a foreign polypeptide further includes isolating and disrupting the cultured Bacillus subtilis to obtain a cell lysate, and then purifying the foreign polypeptide from the cell lysate by sequentially using cation exchange chromatography and heparin-agarose (HA) chromatography. [Brief description of the drawings]
[0025] [Figure 1] 1 is a schematic diagram of a plasmid construction vector (10.4 kb) expressing the H6-DnaE-bFGF insert expression cassette according to one embodiment of the present invention, where ori=Bacillus subtilis origin of replication, AmpR=ampicillin resistance gene, lacI=lacI gene, T7 RNAP=T7 RNA polymerase gene, bFGF=bFGF gene, Asp DnaE=Asp DnaE intein, H6=6xHis tag, RBS=ribosome binding site, and the arrow indicates the direction of gene expression. [Diagram 2] 2 shows the results of immunoblotting of bFGF protein in Bacillus subtilis host cell lysate samples according to one embodiment of the present invention. Lanes 0h, 2h, 4h, 6h and 8h represent samples collected from cultures 0h, 2h, 4h, 6h and 8h after induction, respectively. Each lane was sampled with 5μl of cell lysate. Also, lane-ve represents 5μl of cell lysate obtained from pECBS1 vector culture 8 hours after induction. [Diagram 3]FIG. 3 shows a time course study of B. subtilis bFGF culture in a shake flask according to one embodiment of the present invention. Culture samples were taken before and at different times after IPTG induction. FIG. 3A shows the Western blot analysis of bFGF present in cell lysate (CL) samples. Each lane was sampled with 5 μl of cell lysate. FIG. 3B shows the quantification of cell activity and bFGF. (--●--) indicates the detected bFGF level, and CFU stands for colony forming unit. Viable cell counts were measured on normal agar plates and on plates supplemented with kanamycin, and are shown as (--●--) and (-■-), respectively. Transformant growth tests were performed in triplicate. Error bars are also shown. [Figure 4] Figure 4 shows a time course study of bFGF protein expression in Bacillus subtilis by fed-batch fermentation according to one embodiment of the present invention. Culture samples were taken before and at different times after IPTG induction. Figure 4A shows the results of a Western blot test for bFGF present in cell lysate (CL) samples. Each lane was sampled with 5 μl of cell lysate. Figure 4B shows the quantification of cell activity and bFGF. (--●--) indicates the detected bFGF level, and CFU stands for colony forming unit. Viable cell counts were determined on normal agar plates and on plates supplemented with kanamycin, and are shown as (--●--) and (-■-), respectively. Growth tests of transformants were performed in triplicate. Error bars are also shown. [Diagram 5] FIG. 5 shows the molecular size as measured by mass spectrometry for a purified bFGF sample derived from the pECBS1-H6-DnaE-bFGF construct according to one embodiment of the present invention. [Figure 6] 6 shows the experimental results of the mitogenic activity of bFGF protein according to one embodiment of the present invention, showing the effect of different concentrations of purified bFGF protein samples from the pECBS1-H6-DnaE-bFGF construct on the proliferation of fibroblast cells. [Figure 7]FIG. 7 shows the results of enzyme digestion characterization of the construct pECBS1-H6-DnaE-bFGF. [Figure 8] Figure 8 shows the WB results of bFGF protein expression using H6 and CBD affinity tags, respectively. Lanes 0h, 4h, and 8h show samples collected from cultures 0h, 4h, and 8h after induction, respectively, and lanes +ve and -ve show positive and negative controls, respectively. [Figure 9] Figure 9 shows the WB results of bFGF protein expression using H6 and GST affinity tags, respectively. Lanes 0h, 4h, and 8h represent samples collected from cultures 0h, 4h, and 8h after induction, respectively, and lanes +ve and -ve represent positive and negative controls, respectively. [Figure 10] FIG. 10 shows the results of purification using heparin-agarose chromatography alone. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] The following describes expression systems and methods that can be used to express a variety of foreign polypeptides, particularly native foreign polypeptides, which satisfy at least one need that exists in the art.
[0027] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way.
[0028] Unless expressly defined otherwise, terms used herein are to be understood according to their ordinary meaning in the art to which they pertain, and unless otherwise specified or indicated in the context, nouns unmodified by quantifiers refer to one / one kind or more / plural kinds.
[0029] Standard techniques and procedures are generally performed according to common methods and several common references in the field (see generally Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
[0030] In one embodiment, the present invention provides a nucleic acid construct, the nucleic acid construct comprising an insert, the insert comprising, from the 5' end to the 3' end, a polynucleotide sequence encoding a short peptide affinity tag, a trans-splicing intein derived from Anabaena, and a foreign polypeptide, the short peptide affinity tag being the N-extein of the trans-splicing intein, and the foreign polypeptide being the C-extein of the trans-splicing intein.
[0031] It should be noted that, where no conflict exists, the implementations and features of the implementations of the present application may be combined with each other.
[0032] Intein Inteins are protein elements that can be automatically excised from host proteins and catalyze the ligation of flanking sequences by peptide bonds.
[0033] The intein applicable to the present invention can be a trans-splicing intein from Anabaena. In one embodiment, the intein can be an intein (Asp DnaE) from Anabaena DNA polymerase III unit.
[0034] The term "trans-splicing intein" as used herein means an intein with trans-splicing activity. Inteins are divided into integral inteins and split inteins depending on the form in which they exist. The former has two splicing regions present in the same polypeptide fragment. In contrast, the latter has two splicing regions present in different polypeptide fragments, and is therefore called split inteins. The integral intein exerts a cis-splicing effect, whereas the split intein exerts a trans-splicing effect. Split inteins are also called trans-splicing inteins.
[0035] The term "Anabaena DNA polymerase III unit intein" as used herein refers to an intein derived from Anabaena DNA polymerase III unit. In one aspect, the nucleotide encoding the intein of the present invention may have or include a sequence as shown in SEQ ID NO:1 or a complementary sequence thereof. Alternatively, it may have or include a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the nucleotide sequence as shown in SEQ ID NO:1 or a complementary sequence thereof. Alternatively, it may be composed of the above nucleotide sequence. In one aspect, the intein may have or include an amino acid sequence as shown in SEQ ID NO:2. Alternatively, it may have or include an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the amino acid sequence as shown in SEQ ID NO:2. Alternatively, it may be composed of the above amino acid sequence.
[0036] Foreign Polypeptides As used herein, the terms "foreign polypeptide," "foreign protein," "heterologous polypeptide," and "heterologous protein" are used interchangeably. These are polypeptides or proteins that are not naturally expressed in a host cell, but are added artificially or expressed in a host cell by techniques such as gene transfer.
[0037] In some embodiments, the heterologous polypeptide can be, for example, an enzyme, a cytokine (e.g., fibroblast growth factor), a hormone (e.g., calcitonin, erythropoietin, thrombopoietin, human growth hormone, epidermal growth factor, etc.), an interferon, or other protein having therapeutic, nutritional, agricultural, or industrial use. Other heterologous polypeptides can be antibodies, antibody fragments, and drug proteins. The heterologous polypeptide can also be a polypeptide fragment.
[0038] In one embodiment, the heterologous polypeptide applicable to the present invention may be fibroblast growth factor (FGF), a polypeptide consisting of approximately 150 to 200 amino acids, which exists in two closely related forms: basic fibroblast growth factor (bFGF) and acidic fibroblast growth factor (aFGF).
[0039] In one embodiment, the heterologous polypeptide applicable to the present invention can be a basic fibroblast growth factor, in particular human bFGF, more particularly native human bFGF. In one aspect, the bFGF of the present invention can have or comprise a nucleotide sequence as shown in SEQ ID NO:3. Alternatively, it can have or comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the nucleotide sequence as shown in SEQ ID NO:3. Alternatively, it can be composed of the above nucleotide sequence.
[0040] In one aspect, the bFGF of the present invention may have or comprise the amino acid sequence shown in SEQ ID NO: 4. Alternatively, it may have or comprise an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence shown in SEQ ID NO: 4. Alternatively, it may consist of the above amino acid sequence.
[0041] Affinity Tags As used herein, the terms "affinity tag", "purification tag" and "protein tag" can be used interchangeably. These are proteins or polypeptides that are expressed in fusion with a protein of interest during the recombinant protein production process. Affinity tags can be used to promote the solubility and stability of the protein of interest, facilitating its detection and purification.
[0042] Without intending to be bound by theory, the present invention has unexpectedly found that short peptide affinity tags with relatively small molecular weights are beneficial for obtaining mature and biologically identical (native) foreign proteins or polypeptides.
[0043] In some embodiments, affinity tags applicable to the present invention can be short peptide affinity tags and can have a length of about 4 to 15 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) amino acids. In some embodiments, the short peptide affinity tag is a HIS tag, an HA tag (e.g., YPYDVP), a FLAG tag (e.g., DYKDDDDK), an HSV tag (e.g., QPELAPEDPED), a MYC tag (e.g., ILKKATAYIL or EQKLISEEDL), a V5 tag (e.g., GKPIPNPLLGLDST), an Xpress tag (e.g., DLDDDDK or DLYDDDDK), a Thrombin tag (e.g., LVPRGS), a BAD (biotin acceptor domain) (e.g., GLNDIFEAQKIEWHE), a Factor Xa tag (e.g., IEGR or IDGR), a VSVG tag (e.g., YTDIEMNRLGK), an SV40 These include, but are not limited to, NLS tags (e.g., PKKKRKV or PKKKRKVG), protein C tags (e.g., EDQVDPRLIDGK), S tags (e.g., KETAAAKFERQHMDS), SB1 tags (e.g., PRPSNKRLQQ), etc. In one aspect, the affinity tag can be a 5-15xHis tag, and more specifically, a 6xHis tag (H6).
[0044] In some embodiments, the short peptide affinity tag of the invention is the N-extein of a trans-splicing intein and the foreign polypeptide is the C-extein of the trans-splicing intein. In one example, the H6 tag is fused to the N-terminus of the Asp DnaE intein and bFGF is fused to the C-terminus of the Asp DnaE intein.
[0045] The bFGF coding sequence is first designed and then fused to the C-terminus of the intein. The short peptide affinity tag serves as an anchor for the purification of the expressed protein. Experiments have shown that when a large GST or CBD tag is fused to the N-terminus of the DnaE intein, only the precursor aggregate form is obtained. In contrast, when the N-extein is changed to a short peptide affinity tag (e.g., H6 tag) with a small size, surprising results are obtained. The expressed bFGF is not only in a soluble form, but also in a mature state and has a high production amount (see Figures 2, 3A and 3B). Without intending to be bound by theory, changing the N-extein to a relatively small short peptide affinity tag may change the conformation of the entire fusion protein, which favors the separation of the C-extein and avoids the formation of inclusion bodies.
[0046] Expression vector In one embodiment, the present invention provides an expression vector, which comprises a nucleic acid construct of the present invention.
[0047] As used herein, the terms "vector", "expression vector", "recombinant vector" and "recombinant system" are used interchangeably. The terms refer to a vehicle that allows the manipulation or introduction of a polynucleotide or DNA molecule into a host cell. A vector can be a linear or circular polynucleotide, a large polynucleotide, or any other type of structure. For example, it can be DNA or RNA derived from a viral genome, a virion, or any other biological structure that allows the DNA to be manipulated or introduced into a cell.
[0048] As will be appreciated by those skilled in the art, there is no particular limitation on the type of vector that can be applied, as long as the vector is a cloning vector that can be applied for propagation and obtain a sufficient polynucleotide or gene construct, or an expression vector that can be applied for purification of fusion proteins in different heterologous organisms. In one embodiment, suitable vectors according to the present invention include prokaryotic expression vectors. For example, prokaryotic expression vectors include, but are not limited to, pET14, pET21, pET22, pET28, pET42, pMAL-2c, pTYB2, pGEX-4T-2, pGEX-6T-1, pQE-9, pBAD-his, pBAD-Myc, pECB-based vectors, pRB-based vectors, and the like, such as pUC18, pUC19, Bluescript and its derivatives, mp18, mp19, pBR322, pBR374, pMB9, CoIE1, pCR1, RP4, phage, and "shuttle" vectors (e.g., pSA3 and pAT28).
[0049] In one embodiment, the present invention further contemplates a shuttle vector. As used herein, the term "shuttle vector" refers to a vector capable of replication and amplification in two different host cells (e.g., E. coli and Bacillus subtilis). This allows the same expression vector to be introduced into different host cells. Shuttle vectors of the present invention can include, but are not limited to, pECBS1.
[0050] Typically, the vector configuration may include one or more expression control elements such as (but not limited to) a promoter, an enhancer, an operon, a ribosome binding site, and a transcription termination sequence.
[0051] Exemplary promoters applicable to the present invention may include promoters active in prokaryotes, such as the T7 promoter, the phoA promoter, β-lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system, and hybrid promoters such as the tac promoter.
[0052] Exemplary operons applicable to the present invention include, but are not limited to, lactose operon, arabinose operon, tryptophan operon, etc. The lactose operon is a group of genes involved in the breakdown of lactose, and is composed of repressor and operator sequences of the lactose system, which allows a series of genes related to lactose metabolism to be synchronously regulated.
[0053] As used herein, the term "ribosome binding site" (abbreviated as RBS) refers to a sequence located upstream of the start codon of an mRNA and available for binding to a ribosome at the initiation of translation.
[0054] The expression vector according to the invention may further comprise a polynucleotide encoding a marker protein. Marker proteins applicable to the present invention include proteins that provide antibiotic resistance or resistance to other toxic compounds. Examples of marker proteins that provide antibiotic resistance include neomycin phosphotransferase, which phosphorylates neomycin and kanamycin, or hpt, which phosphorylates hygromycin, or proteins that provide resistance to, for example, bleomycin, streptomycin, tetracycline, chloramphenicol, ampicillin, gentamicin, geneticin (G418), spectinomycin or blasticidin. In one case, the protein confers resistance to chloramphenicol. For example, the protein is a gene from E. coli, designated CmR, as described in Nilsen et al, J. Bacteriol, 178:3188-3193, 1996.
[0055] The polynucleotide encoding the target polypeptide can be cloned into the vector of the present invention by using standard techniques known to those skilled in the art. For example, the polynucleotide encoding the target polypeptide can be produced by using polymerase chain reaction (PCR). Methods for PCR manipulation are known in the art.
[0056] In some embodiments, the nucleic acid construct of the present invention further comprises a first cloning site located upstream of the insert and a second cloning site located downstream of the insert, the first cloning site and the second cloning site allowing for insertion of the nucleic acid construct into an expression vector.
[0057] The cloning site allows the cloning of a polynucleotide encoding a heterologous polypeptide. Preferably, the cloning sites are combined to form a multiple cloning site. As used herein, the term "multiple cloning site" refers to a nucleic acid sequence that contains a series of two or more restriction endonuclease target sequences positioned adjacent to each other. The multiple cloning site contains the restriction endonuclease targets and allows the insertion of fragments with blunt ends, sticky 5' ends or sticky 3' ends. The insertion of the target polynucleotide is performed by standard techniques in molecular biology, for example as described by Sambrook et al. (Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press, 1989) and / or Ausubel et al. (Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience, 1988).
[0058] The term "restriction enzyme" or "restriction endonuclease" as used herein refers to an enzyme that can recognize and attach to a specific deoxyribonucleotide sequence and cleave the phosphodiester bond between two deoxyribonucleotides at specific sites in each strand. The cleavage method involves cleaving the bond between the sugar molecule and the phosphate, generating a cut in each of the two DNA strands, but not destroying the nucleotides and bases. There are two types of cleavage methods: one that can generate sticky ends with overhanging single-stranded DNA, and one that can generate blunt ends with flat ends without overhangs. The cleaved DNA fragments can be ligated with DNA ligase, so that different restriction fragments on the chromosome or DNA are joined by splicing action. Restriction enzymes applicable to the present invention can include, but are not limited to, EcoRI, PstI, XbaI, BamHI, HindIII, TaqI, NotI, HinfI, Sau3A, PovII, SmaI, HaeIII, AluI, SalI, Dra, etc.
[0059] Methods for ligating nucleic acids are known to those of skill in the art and are described, for example, in Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press, 1989, and / or Ausubel et al. (eds.), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988). In one instance, a ligase (e.g., T4 DNA ligase) is used to ligate nucleic acids.
[0060] host cell In some embodiments, the present invention provides a transformed host cell, which comprises an expression vector of the present invention. Bacillus subtilis is endotoxin-free and therefore is recognized as "generally recognized as safe". Thus, in one embodiment of the present invention, Bacillus subtilis is used as the host cell. The inventors of the present invention have surprisingly found that by adopting the structure of the nucleic acid construct of the present invention, Bacillus subtilis can promote automatic excision of inteins and exteins, and can obtain a satisfactory expression level of native foreign polypeptides / proteins. This solves the problem of low expression level of foreign polypeptides / proteins in Bacillus subtilis.
[0061] In some aspects, the present invention provides a method for obtaining a transformed Bacillus subtilis, comprising contacting Bacillus subtilis with an expression vector of the present invention under conditions allowing the expression vector to be introduced into Bacillus subtilis. Those skilled in the art are aware and capable of adjusting the appropriate conditions based on the type of expression vector and host cell.
[0062] As used herein, the term "transformation" refers to the introduction of DNA into a prokaryotic host, either as an extrachromosomal element or integrated into the chromosome, so that the DNA is replicable. Depending on the host cell used, transformation is performed using standard techniques appropriate for that cell. Typically, a calcium treatment using calcium chloride is applied to bacterial cells that contain a tight cell wall barrier. Another method used for transformation is the use of polyethylene glycol / DMSO. Yet another technique that can be used is electroporation.
[0063] The prokaryotic host cells for producing the foreign polypeptide of the present invention are cultured in a medium known in the art and adapted for culturing the host cells. An example of a suitable medium may include Luria-Bertani (LB) medium supplemented with necessary nutrients. In some embodiments, the medium further includes a selection agent selected based on the expression vector constructed to selectively allow the growth of the prokaryotic cells containing the expression vector. For example, ampicillin and / or kanamycin are added to the medium used for growing the cells, so that the cells express ampicillin and / or kanamycin resistance genes. The medium may further include any necessary supplements other than carbon, nitrogen and inorganic phosphorus sources at appropriate concentrations. The supplements may be added alone or in a mixture with other supplements or media (e.g., complex nitrogen sources).
[0064] Methods for producing foreign polypeptides In some embodiments, the present invention provides a method for producing a foreign polypeptide, the method comprising culturing a transformed Bacillus subtilis of the present invention under conditions allowing expression of the foreign polypeptide.
[0065] For gene product accumulation expression, the host cells are cultured under conditions sufficient for accumulation of the gene product. These conditions may include, for example, temperature, nutrient, and cell density conditions that allow cellular expression and protein accumulation. Additionally, as known to those skilled in the art, these conditions are conditions that allow the cells to carry out basic cellular functions such as transcription and translation, and intracellular expression.
[0066] The prokaryotic host cells are cultured at an appropriate temperature. For example, for the culture of Bacillus subtilis, a typical temperature is about 20° C. to about 39° C. In one embodiment, the temperature is about 25° C. to about 37° C., for example, 37° C.
[0067] Induction is typically achieved by culturing the cells until a particular optical density (e.g., A55tl of approximately 80-100) is reached, at which point induction is initiated (e.g., by addition of an inducer, repressor, inhibitor, or depletion of a medium component, etc.) to induce expression of the gene encoding the heterologous polypeptide.
[0068] After enrichment of the product, the cells present in the culture may be mechanically disrupted using any mechanical technique known in the art to release the protein from the host cells. Optionally, other disruption techniques may be used, including but not limited to alkaline lysis, SDS lysis, etc. The cell lysis solution for disrupting the cells may include but is not limited to Tris-HCl, EDTA, NaCl, glucose, lysozyme, etc. Optionally, the lysate is incubated for a sufficient time to release the heterologous polypeptide contained within the cells before harvesting the product.
[0069] The disruptate may be further treated, for example by dilution with water, addition of buffers or flocculants, adjustment of pH, or altering or maintaining the temperature of the disruptate / homogenate in preparation for subsequent recovery steps.
[0070] In a subsequent step, the heterologous polypeptide is recovered from the disruptant in a manner that minimizes the amount of cell fragments and products recovered. Recovery can be by any method. In one embodiment, this can include settling refractile particles containing the heterologous polypeptide or collecting the supernatant containing the soluble products. An example of settling can be centrifugation. Prior to adsorption or settling, recovery is performed in the presence of a reagent that disrupts the outer cell wall, increasing permeability and allowing more solids to be recovered. Examples of such reagents include chelating agents such as ethylenediaminetetraacetic acid (EDTA) or zwitterions such as zwitterionic detergents (e.g. ZWITTERGENT 316® detergent). In one embodiment, recovery is performed in the presence of EDTA.
[0071] In one embodiment, the method may further include, if necessary, simultaneously solubilizing and refolding the polypeptide after separation of aggregated heterologous polypeptide. Preferably, the soluble product can be recovered by standard techniques such as immunoaffinity or ion exchange column fractionation, ethanol precipitation, reverse phase HPLC, silica or cation exchange resin (e.g., DEAE) chromatography, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, and gel filtration, e.g., using SEPHADEX® G-75 or heparin-agarose (HA) chromatography.
[0072] In one embodiment, the method for producing a foreign polypeptide of the present invention further comprises purifying the foreign polypeptide from the cell lysate by sequentially using cation exchange chromatography and heparin-agarose (HA) chromatography. Surprisingly, the inventors found that by removing most of the housekeeping proteins using cation exchange chromatography before using heparin-agarose chromatography, and then removing high concentrations of salt by dialysis, it is possible to obtain bFGF protein with unpredictable high purity.
[0073] Although B. subtilis is an attractive host system for protein production due to its endotoxin-free nature, previous studies have demonstrated that it is difficult to obtain high levels of intracellular expression of soluble heterologous proteins. Although many researchers have developed inteins and their applications in protein expression, the mechanism of action of inteins in different host systems is not fully clear. Therefore, the inventors attempted to express endotoxin-free recombinant proteins in bacterial host systems for research and commercial purposes. Compared with other methods, protein expression using inteins is the simplest and most economically viable method for producing recombinant proteins with biologically identical structures. It can also ensure high biological activity and prevent the occurrence of undesirable immune responses in animal subjects.
[0074] In order to overcome the shortcomings of the prior art and improve the predictability and effectiveness of intein-mediated protein purification systems, the inventors have created a completely new protein expression and purification system. In this system, an intein (Asp DnaE) from Anabaena species, particularly from the DNA polymerase III unit, is used to promote intracellular expression of a foreign protein (e.g., human bFGF protein) in Bacillus subtilis. In addition, a short peptide affinity tag (e.g., 6xHis tag) is added to the N-terminus of the fusion protein to improve the efficiency of protein purification and obtain an active native foreign protein (e.g., human bFGF protein). If a foreign protein such as human bFGF is expressed using the construct provided by the present invention, the expression efficiency of a biologically active foreign protein (e.g., human bFGF protein) can be significantly improved. In addition, the occurrence of inclusion bodies is reduced, the purification steps are simplified, and the purification cost is significantly reduced. The inventors have further demonstrated the following through experiments. That is, in a 4L-scale fermentation experiment, the construct and protein purification system of the present invention significantly increased the total production of foreign proteins (e.g., human bFGF protein) compared with shake flask culture. In addition, the cell viability remained stable throughout the entire induction period. Therefore, it is particularly suitable for use in large-scale culture, and has achieved unpredictable technical effects.
[0075] Exemplary sequences according to the invention are shown in the table below.
[0076] [Table 1] EXAMPLES
[0077] The present invention will now be described by the following examples, which are intended as illustrative examples only and are not intended to limit the scope of the invention.
[0078] The E. coli strain DH5α was purchased from New England Biolabs (Ipswich, MA). The B. subtilis strain WB800 was obtained as previously reported. Synthetic DNA fragments, restriction enzymes, and bFGF antibody were purchased from Thermo Fisher Scientific (Ipswich, MA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
[0079] Example 1: Construction of expression vectors and transformation of host cells Construction and design of E. coli / B. subtilis expression shuttle vectors pRB374 and pBR322 were used as the starting vectors for E. coli / B. subtilis expression shuttle vectors, respectively. Specifically, pECBS1 was constructed by the following modification steps. First, pRB374 (5.9 kb) was digested with SalI and BglII. After digesting the two sites with the same SalI and BglII, the T7 RNA polymerase-Lac promoter-LacI gene-LacI gene produced by shotgun polymerase chain reaction was inserted into the pECBS1 vector. q The pECBSi vector was generated by replacing the promoter-bleomycin resistance gene-neomycin resistance gene fragment (5.3 kb) with the promoter-bleomycin resistance gene-neomycin resistance gene fragment (5.3 kb). The pECBSi vector and the pBR322 vector were then digested with EcoRI and BglI, respectively, and the digested fragment of pECBSi was replaced with the fragment obtained by digestion of pBR322 (4.3 kb) to generate the pECBS1 shuttle vector.
[0080] Construction of bFGF expression vector The E. coli / B. subtilis expression shuttle vector (pECBS1-H6-DnaE-bFGF) was constructed as follows. Thermo Fisher Scientific synthesized a DNA fragment encoding the EcoRI-T7 promoter (T7)-lactose operon (LacO)-ribosome binding site (RBS)-6x-His tag (H6)-Asp-DnaE int-c(DnaE)-bFGF-T7 transcription terminator-XbaI sequence shown in SEQ ID NO:5. Next, the synthesized DNA fragment was digested with EcoRI and XbaI, and then the ligation of the B. subtilis / E. coli shuttle vector pECBS1 was digested with the same two types of restriction enzymes. Finally, the pECBS1-H6-DnaE-bFGF construct was obtained (see FIG. 1). The results of enzyme cleavage analysis of the obtained construct are shown in FIG. 7.
[0081] Transformation of Bacillus subtilis A single colony of WB800 was transferred to 5 ml of medium A (containing 1x Spizizen salt solution, 0.5% glucose, 0.005% tryptophan, 0.02% casamino acids, 0.5% yeast extract, 0.8% arginine, and 0.4% histidine) and grown overnight at 37°C and 200 rpm. 0.5 ml of the overnight culture was then subcultured into 50 ml of medium A and grown at 37°C and 200 rpm until A600=1.7. 1 ml of 87% glycerol was then added to the 10 ml culture and placed on ice for 15 min. 1 ml of the culture was then subcultured into 20 ml of medium B (containing 1x Spizizen salts, 0.5% glucose, 0.0005% tryptophan, 0.01% casamino acids, 0.1% yeast extract, 2.5 mM MgCl2, 0.5 mM CaCl2) and incubated at 30°C and 150 rpm for 2 hours. 1 ml of the culture was then transferred to a microcentrifuge tube and incubated at room temperature for 5 minutes with EGTA at a final concentration of 1 mM. 2 ug of plasmid DNA was then added to 1 ml of competent WB800 and allowed to grow at 37°C and 200 rpm for another 2 hours. The transformed WB800 was then collected after centrifugation at 5000 rpm and room temperature and resuspended in 100 ul of culture supernatant. The transformed WB800 was then plated onto kanamycin-resistant plates and incubated at 37°C overnight.
[0082] Example 2: Expression of bFGF Shake flask culture The B. subtilis transformants were grown at 37°C (250 rpm) in 200 ml of 2x LB medium supplemented with 25 μg / ml kanamycin. When the A600 value reached 1.0, IPTG was added to a final concentration of 0.2 mM. After that, 1 ml medium samples were collected at 3-hour intervals and used for bFGF expression analysis. The cell pellet was resuspended in 200 μl of resuspension buffer (50 mM Tris-Cl, 200 mM EDTA, pH 8.0) and incubated on ice for 5 min. The mixture was then treated with 120 μl of lysozyme solution (10 mg / mL) for 20 min at 37°C. Then, 80 μl of lysis buffer (10 mM EDTA, 10% Triton X-100 and 50 mM Tris-Cl, pH 8.0) was added. The filled tube was then gently inverted and centrifuged at 14800 rpm for 5 min. The expression status of bFGF protein in the cell lysate samples was then analyzed by Western blot.
[0083] In order to successfully express soluble bFGF protein, the inventors further tested different combinations of intein and foreign polypeptide in experiments, and finally found that Asp DnaE intein was effective. In addition, bFGF was selectively fused to the C-terminus of Asp DnaE intein, because the in vitro excision at the C-terminus of DnaE can be controlled by changing pH or treating with reducing agent. In addition, the inventors tried several different expression tags, including GST, chitin binding domain (CBD) and H6 affinity tag. When the first two expression tags were used, the construct only produced an insoluble form of the precursor (see Figures 8 and 9). On the other hand, when the relatively small size of H6 tag was used, the experiment showed positive expression of mature and biologically identical bFGF (see Table 2 for details). The results of the shake flask culture experiment (see FIG. 2) showed that the construct pECBS1-H6-DnaE-bFGF expressed a satisfactory level of the final product bFGF upon induction, and no precursor form was detected by Western blot (see FIG. 8 and FIG. 9).
[0084] [Table 2]
[0085] Fed-batch fermentation The B. subtilis transformants were grown at 37°C (rotation speed 250 rpm) in 200 ml of 2x LB medium supplemented with 25 μg / ml kanamycin until A600=1.0. 50 ml of the culture was then transferred to a 2 L flask (containing 450 ml of 2x LB medium supplemented with 25 μg / ml kanamycin) and continued to grow at 37°C (rotation at 250 rpm) until A600 value of 1.0 was reached. The entire culture was then transferred to a 5 L fermenter filled with 3.5 L of 2x LB medium supplemented with 25 μg / ml kanamycin and the pH of the culture was maintained at 7.0 by adding 1 M NaOH. The pO2 value (oxygen partial pressure) of the culture was 1.5 vvm. The pH of the culture was also maintained at 7.0 by adding 50% glucose feed solution if the pH started to rise. After A600=8, IPTG was added to a final concentration of 0.2 mM for induction, and pH was maintained with 1 M H2SO4. Culture samples were collected at 2-hour intervals and used for analysis of bFGF expression.
[0086] As a result, it was found that both the bFGF protein expression level and cell mass of Bacillus subtilis were significantly increased. Specifically, by switching from shake flask culture (Figure 3) to large-scale culture (Figure 4), the total bFGF protein production and the final colony forming units (CFU) of the expression construct were increased by 2-fold (from 64 mg / L to 113 mg / L) and 6-fold, respectively. As is clear from the above, the construct obtained in the present invention has provided unpredictable technical effects in both shake flask culture and large-scale fermentation culture.
[0087] Example 3: Purification and structural determination of bFGF protein Cation exchange chromatography and heparin-agarose chromatography were used to purify bFGF. First, the protein concentration of the eluted fractions was measured using a Nanodrop Microvolume spectrophotometer. The eluted fractions with significant values (approximately 1 mg / ml) were pooled and dialyzed against 0.1x PB. The purified bFGF band was obtained by electrophoresis on a 10% SDS-PAGE gel stained with Coomassie Brilliant Blue R-250. The band containing bFGF protein was then collected from the SDS-PAGE gel and used for subsequent analysis by LC-MS.
[0088] Western blot analysis showed that the soluble bFGF protein extracted from the lysate had the same molecular weight as the bFGF protein purchased from Thermo Fisher Scientific (Figure 4). The purified bFGF protein sample was subjected to N- and C-terminal protein sequencing by LC-MS and MALDI-TOF mass measurement. As a result, the final product of bFGF protein obtained from the expression of the H6-DnaE-bFGF construct had a biological structure consisting of 146 amino acids (Table 2). In addition, the size was 16.4 kda (Figure 5), which was consistent with the natural human bFGF protein. Compared to the case where purification was performed using only heparin-agarose chromatography (Figure 10), the present invention obtained a highly pure bFGF protein by purification using cation exchange chromatography and heparin-agarose chromatography.
[0089] Example 4: Biological activity measurement of bFGF protein The effect of purified bFGF protein on the proliferation of NIH / 3T3 fibroblasts was measured by the MTT method (also called MTT colorimetric method). The specific steps were as follows: NIH / 3T3 cells (at a density of 2 × 10 4The cells (referred to as β-cells) were transplanted into a 96-well microplate and starved in DMEM medium supplemented with 1% fetal bovine serum at 37°C and 5% CO2 for 24 h, after which the cells were treated with different concentrations of bFGF for 3 days. Next, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at a final concentration of 0.5 mg / mL was added to each well of the microplate and incubated at 37°C and 5% CO2 for 4 h. After that, all the solutions were removed from the plate and 150 μl of DMSO was added to dissolve the purple crystals. The plate was then shaken continuously in the dark for 10 min, and the absorbance was read at 570 nm by enzyme-linked immunosorbent assay.
[0090] As a result, the purified bFGF protein expressed in Bacillus subtilis was able to induce cell proliferation in NIH / 3T3 cells (Figure 6), and was also able to induce proliferation in human mesenchymal stem cells (data not shown). As is clear from the above, the purified bFGF protein obtained in the present invention had biological activity (mitogenesis promoting activity).
[0091] As can be seen from the above results, the purified bFGF protein of the present invention has the same primary sequence of 146 amino acids as the wild protein, and is in the form of a mature soluble protein. It also has high biological activity in inducing the proliferation of NIH / 3T3 cells. In addition, the inventors simultaneously tried fermentation cultures of different scales, and obtained unpredictable technical effects in both the expression amount of bFGF protein and the cell amount.
[0092] Moreover, those skilled in the art will recognize that the present invention can be embodied in other specific forms without departing from the spirit or central characteristics of the present invention. The above description of the present invention discloses only exemplary embodiments, and it should be understood that other variations are also considered within the scope of the present invention. Thus, the present invention is not limited to the specific embodiments described in detail herein. On the contrary, the scope and content of the present invention should be defined with reference to the appended claims.
Claims
1. 1. A nucleic acid construct comprising an insert, the insert comprising, from its 5'-end to its 3'-end, a polynucleotide sequence encoding a short peptide affinity tag, a trans-splicing intein derived from Anabaena sp., and a foreign polypeptide, the short peptide affinity tag being an N-extein of the trans-splicing intein, and the foreign polypeptide being a C-extein of the trans-splicing intein.
2. 2. The nucleic acid structure according to claim 1, wherein the intein is an intein of the Anabaena DNA polymerase III unit (Asp DnaE).
3. 3. The nucleic acid construct of claim 1 or 2, wherein the intein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:
2.
4. The nucleic acid structure according to claim 1 or 2, wherein the intein comprises the sequence shown in SEQ ID NO:
2.
5. The nucleic acid construct according to any one of claims 1 to 4, wherein the foreign polypeptide is basic fibroblast growth factor (bFGF).
6. The nucleic acid structure according to any one of claims 1 to 5, wherein the short peptide affinity tag has a length of 4 to 15 amino acids and is a 5 to 15xHis tag.
7. The nucleic acid structure according to any one of claims 1 to 6, further comprising one or more elements selected from the group consisting of a promoter, an operon, an enhancer, and a ribosome binding site.
8. The nucleic acid construct according to any one of claims 1 to 7, comprising a nucleotide sequence encoding from the 5' end to the 3' end: T7 promoter-lactose operon-ribosome binding site (RBS)-6xHis tag-Asp DnaE intein-bFGF-T7 transcription terminator.
9. The nucleic acid construct according to any one of claims 1 to 8, further comprising a first cloning site located upstream of the insert and a second cloning site located downstream of the insert, the first cloning site and the second cloning site enabling insertion of the nucleic acid construct into an expression vector.
10. An expression vector comprising the nucleic acid construct according to any one of claims 1 to 9.
11. 11. A transformed Bacillus subtilis comprising the expression vector of claim 10.
12. A method for producing a foreign polypeptide comprising culturing the transformed Bacillus subtilis of claim 11 under conditions allowing expression of the foreign polypeptide.
13. The method for producing a foreign polypeptide described in claim 12, further comprising isolating and disrupting the cultured Bacillus subtilis to obtain a cell lysate, and then purifying the foreign polypeptide from the cell lysate by sequentially using cation exchange chromatography and heparin-agarose (HA) chromatography.
Citation Information
Patent Citations
One-component and two-component dnapoliii replicases and their uses
JP2007532116A
Intein-mediated protein purification
JP2016504417A
Method and means for expressing basic fibroblast growth factor that is authentic and biologically active in bacillus subtilis
JP2019195327A
Split inteins with exceptional splicing activity
JP2019506163A
Macrocyclic compounds with a hybrid peptidic / non-peptidic backbone and methods for their preparation
WO2012100176A2
